Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas

Targeting the epigenome has been considered a compelling treatment modality for several cancers, including gliomas. Nearly 80% of the lower-grade gliomas and secondary glioblastomas harbor recurrent mutations in isocitrate dehydrogenase (IDH). Mutant IDH generates high levels of 2-hydroxyglutarate (...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jong-Whi, Turcan, Şevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826741/
https://www.ncbi.nlm.nih.gov/pubmed/31652645
http://dx.doi.org/10.3390/cancers11101616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826741/
https://www.ncbi.nlm.nih.gov/pubmed/31652645
http://dx.doi.org/10.3390/cancers11101616

Ejemplares similares